IOPROMIDE

Details

Stereochemistry	MIXED
Molecular Formula	C18H24I3N3O8
Molecular Weight	791.1119
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COCC(=O)NC1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I

InChI

InChIKey=DGAIEPBNLOQYER-UHFFFAOYSA-N

InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020220s041,021425s024lbl.pdf
Curator's Comment: Description was created based on several sources, including: http://www.drugbank.ca/drugs/DB09156 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df917c3a-59a2-4ed1-8470-8a5394c73325

Iopromide is a molecule used as a contrast medium. It is a low osmolar, non-ionic contrast agent for intravascular use. It is commonly used in radiographic studies such as intravenous urograms, brain computer tomography (CT) and CT pulmonary angiograms (CTPAs). It appears to increase the risk of biguanide induced lactic acidosis. Interleukins are associated with an increased prevalence of delayed hypersensitivity reactions after iodinated contrast agent administration. Most common adverse reactions (>1%) are headache, nausea, injection site and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia, and abnormal vision.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
vessels 1 Target ID: vessels Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020220s041,021425s024lbl.pdf	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Cardiovascular diseases 72 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020220s041,021425s024lbl.pdf	Diagnostic	Approved 8583	ULTRAVIST 150 Approved Use ULTRAVIST® Injection is an iodinated contrast agent indicated for: ULTRAVIST (iopromide) Injection is a radiographic contrast agent indicated for: •Cerebral arteriography and peripheral arteriography (300 mg I/mL) (1.1) •Coronary arteriography and left ventriculography, visceral angiography and aortography (370 mg I/mL) (1.1) •Peripheral venography (240 mg I/mL) (1.2) •Excretory urography (300 mg I/mL) (1.2) •Contrast computed tomography (CT) imaging of head and body (300 mg I/mL and 370 mg I/mL) (1.2) 1.1 Intra-Arterial Procedures* •300 mg I/mL for cerebral arteriography and peripheral arteriography •370 mg I/mL for coronary arteriography and left ventriculography, visceral angiography, and aortography 1.2 Intravenous Procedures* •240 mg I/mL for peripheral venography •300 mg I/mL for excretory urography •300 mg I/mL and 370 mg I/mL for contrast Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated. *For information on the concentrations and doses for the Pediatric Population [see Dosage and Administration (2.3) and Use in Specific Populations (8.4) Launch Date 1995
Urinary system disease 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020220s041,021425s024lbl.pdf	Diagnostic	Approved 8583	ULTRAVIST 150 Approved Use ULTRAVIST® Injection is an iodinated contrast agent indicated for: ULTRAVIST (iopromide) Injection is a radiographic contrast agent indicated for: •Cerebral arteriography and peripheral arteriography (300 mg I/mL) (1.1) •Coronary arteriography and left ventriculography, visceral angiography and aortography (370 mg I/mL) (1.1) •Peripheral venography (240 mg I/mL) (1.2) •Excretory urography (300 mg I/mL) (1.2) •Contrast computed tomography (CT) imaging of head and body (300 mg I/mL and 370 mg I/mL) (1.2) 1.1 Intra-Arterial Procedures* •300 mg I/mL for cerebral arteriography and peripheral arteriography •370 mg I/mL for coronary arteriography and left ventriculography, visceral angiography, and aortography 1.2 Intravenous Procedures* •240 mg I/mL for peripheral venography •300 mg I/mL for excretory urography •300 mg I/mL and 370 mg I/mL for contrast Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated. *For information on the concentrations and doses for the Pediatric Population [see Dosage and Administration (2.3) and Use in Specific Populations (8.4) Launch Date 1995
Cancer 609 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020220s041,021425s024lbl.pdf	Diagnostic	Approved 8583	ULTRAVIST 150 Approved Use ULTRAVIST® Injection is an iodinated contrast agent indicated for: ULTRAVIST (iopromide) Injection is a radiographic contrast agent indicated for: •Cerebral arteriography and peripheral arteriography (300 mg I/mL) (1.1) •Coronary arteriography and left ventriculography, visceral angiography and aortography (370 mg I/mL) (1.1) •Peripheral venography (240 mg I/mL) (1.2) •Excretory urography (300 mg I/mL) (1.2) •Contrast computed tomography (CT) imaging of head and body (300 mg I/mL and 370 mg I/mL) (1.2) 1.1 Intra-Arterial Procedures* •300 mg I/mL for cerebral arteriography and peripheral arteriography •370 mg I/mL for coronary arteriography and left ventriculography, visceral angiography, and aortography 1.2 Intravenous Procedures* •240 mg I/mL for peripheral venography •300 mg I/mL for excretory urography •300 mg I/mL and 370 mg I/mL for contrast Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated. *For information on the concentrations and doses for the Pediatric Population [see Dosage and Administration (2.3) and Use in Specific Populations (8.4) Launch Date 1995

AUC

Value	Dose	Co-administered	Analyte	Population
2.3 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7957519	15 g single, intravenous dose: 15 g route of administration: Intravenous experiment type: SINGLE co-administered:		IOPROMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.2 mg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7957519	80 g single, intravenous dose: 80 g route of administration: Intravenous experiment type: SINGLE co-administered:		IOPROMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.95 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7957519	15 g single, intravenous dose: 15 g route of administration: Intravenous experiment type: SINGLE co-administered:		IOPROMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7957519	80 g single, intravenous dose: 80 g route of administration: Intravenous experiment type: SINGLE co-administered:		IOPROMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
99% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf	unknown, unknown		IOPROMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
124709.092 mg 1 times / day single, intravenous Recommended Dose: 124709.092 mg, 1 times / day Route: intravenous Route: single Dose: 124709.092 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/results/NCT00244140	unknown, 51.9 Health Status: unknown Age Group: 51.9 Sex: M+F Sources: https://clinicaltrials.gov/ct2/show/results/NCT00244140	Sources: https://clinicaltrials.gov/ct2/show/results/NCT00244140

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	substrate 1193	substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1A2 1197 CYP2C19 1119 UGT1A1 479 UGT1A3 470 UGT1A4 399 UGT1A6 343 UGT1A7 249 UGT1A8 323 UGT1A10 331

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
UGT1A1 479	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
UGT1A10 331	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
UGT1A3 470	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
UGT1A4 399	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
UGT1A6 343	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
UGT1A7 249	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no
UGT1A8 323	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021425s030lbl.pdf#page=12 Page: 12.0	no

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63578	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63578
ChemicalBook	CB02620949	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB02620949
ChemicalBook	CB9236567	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9236567
eMolecules	1987243	https://www.emolecules.com/cgi-bin/more?vid=1987243
MolPort	MolPort-005-932-395	https://www.molport.com/shop/molecule-link/MolPort-005-932-395

PubMed

Title	Date	PubMed
Thoracic aortic stent graft: comparison of contrast-enhanced MR angiography and CT angiography in the follow-up: initial results.	2003-07	12835978
Measuring single-kidney glomerular filtration rate on single-detector helical CT using a two-point Patlak plot technique in patients with increased interstitial space.	2003-07	12818847
Prospective comparison of 3-dimensional volume rendered computerized tomography and conventional renal arteriography for surgical planning in patients undergoing laparoscopic donor nephrectomy.	2003-07	12796644
Cortical blindness after contrast-enhanced CT: complication in a patient with diabetes insipidus.	2003-06-19	12812935
[Feasibility and optimization of the combined injection of contrast medium and normal saline with a single-syringe CT injection system].	2003-06	12811699
Open radio-frequency thermal ablation of renal VX2 tumors in a rabbit model using a cooled-tip electrode: feasibility, safety, and effectiveness.	2003-06	12764649
3D contrast-enhanced MR portography and direct X-ray portography: a correlation study.	2003-06	12764642
[Prospects of the use of non-ionic X-ray contrast media during endoscopic retrograde cholangiopancreatography].	2003-05-02	12722628
Isocenter accuracy in frameless stereotactic radiotherapy using implanted fiducials.	2003-05-01	12694848
The nonionic radiocontrast medium iopromide does not release endothelin-1 or activate cardiac mast cells during coronary angiography.	2003-05	12759490
Altered response in renal blood flow and oxygen tension to contrast media in diabetic rats.	2003-05	12752011
Prospective evaluation of carotid artery stenosis: elliptic centric contrast-enhanced MR angiography and spiral CT angiography compared with digital subtraction angiography.	2003-05	12748115
Focal eosinophilic infiltration in the liver: radiologic findings and clinical course.	2003-04-30	12719902
Helical CT of the small bowel with an alternative oral contrast material in patients with Crohn disease.	2003-04-30	12719900
Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater?	2003-04	12697241
Comparison between the efficacy of dimeric and monomeric non-ionic contrast media (iodixanol vs iopromide) in urography in patients with macroscopic haematuria.	2003-04	12664121
1-molar gadobutrol as a contrast agent for computed tomography: results from a comparative porcine study.	2003-04	12649642
Oxidation of pharmaceuticals during ozonation and advanced oxidation processes.	2003-03-01	12666935
Measurement of glomerular filtration rate by low-dose iopromide plasma clearance.	2003-03	12694102
Late-type allergy to Ultravist (iopromid).	2003-03	12653805
Use of iodine-based contrast media in digital full-field mammography--initial experience.	2003-03	12635010
Tourniquet application to facilitate axillary venous access in percutaneous central venous catheterization.	2003-03	12601221
Aortoiliac and renal arteries: prospective intraindividual comparison of contrast-enhanced three-dimensional MR angiography and multi-detector row CT angiography.	2003-03	12601190
Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells.	2003-03	12595799
Gadolinium dimeglumine as a contrast agent for digital subtraction angiography: in vitro hounsfield unit measurement and clinical efficacy.	2003-02	12619187
Superficial endobronchial lung cancer: radiologic-pathologic correlation.	2003-01-07	12514339
Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia.	2003-01	12631011
CT angiography before embolization for hemorrhage in head and neck cancer.	2003-01	12533343
Use of additives to contrast media to improve imaging in plain film and computed tomography urography.	2003-01	12496517
Contrast media effect on cerebral blood flow regulation after performance of cerebral or coronary angiography.	2003	12766361
[Arteries of the uterine cervix in reproductive age in microangiographic studies].	2002-12	12722465
[Arteries of the hilum and parenchymal part of the ovary in reproductive age in microangiographic studies].	2002-12	12722464
Use of near-infrared reflection spectroscopy to study the effects of X-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors.	2002-12	12447004
[A fatal case of anaphylactoid shock after administration of nonionic contrast medium].	2002-11	12508496
Effect of an ionic compared to a non-ionic X-ray contrast agent on platelets and coagulation during diagnostic cardiac catheterisation.	2002-10-10	12372925
Assessment of perfusion of facial microvascular transplants and early detection of ischemia by perfusion-CT scan.	2002-10	12374914
Neurotoxicity of angiographic carbon dioxide in the cerebral vasculature.	2002-10	12352162
Allergies correlated to adverse reactions induced by non-ionic monomeric and ionic dimeric contrast media for contrast enhanced CT examination.	2002-09	12520220
Is same-day sonography of the gallbladder feasible after intravenous urography or contrast-enhanced computed tomography?	2002-09	12216763
Multiplanar spiral CT enterography in patients with Crohn's disease using a negative oral contrast material: initial results of a noninvasive imaging approach.	2002-09	12195478
Two-center clinical study on the effect of chronic renal impairment on safety of iopromide 300 mg iodine/ml.	2002-08	12188331
Electrocardiographic effects of diagnostic imaging agents.	2002-08	12188303
Multi-modal contrast agents: a first step.	2002-08	12188250
Thymic lesions and myasthenia gravis. Diagnosis based on mediastinal imaging and pathological findings.	2002-07	12225479
Contrast enhancement of round atelectases.	2002-07	12225478
Intraindividual comparison of contrast-enhanced electron-beam computed tomography and navigator-echo-based magnetic resonance imaging for noninvasive coronary artery angiography.	2002-07	12111056
[Observing the density increase curve after intravenous contrast medium administration using a bolus triggering system: a method for detection cardiovascular disorders?].	2002-06	12149909
Experimental study of Eudragit mixture as a new nonadhesive liquid embolic material.	2002-04	12133297
[Diagnosis of tumors of the small intestine with the aid of CT contrast enema. Sellink CT technique evaluated in 63 patients].	2002	12174444
[Virtual colonoscopy with multi-detector computerized tomography].	2002	12051079

Patents

Sample Use Guides

In Vivo Use Guide

Intra-Arterial: Maximum Total Dose of Ultravist (iopromide) 300 mgI/mL for Cerebral Arteriography is 150 mL, for Peripheral Arteriography is 250 mL. Maximum Total Dose of Ultravist 370 mgI/mL for Coronary Arteriography and Left Ventriculography is 225 mL. Intravenous: Maximum Total Dose of Ultravist 300 mgI/mL for Excretory Urography is 100 mL. Maximum Total Dose of Ultravist 300 mgI/mL for Contrast Computed Tomography is 200 mL

Route of Administration: Other

In Vitro Use Guide

The thrombin time increased from approximately 20 seconds at an iopromide concentration of 10 mgI/mL, up to 100 seconds at an iopromide concentration of 70 mg I/mL.

Name

Type

Language

PROSCOPE

Preferred Name

English

IOPROMIDE

Official Name

English

ZK 35760

Code

English

IOPROMIDE [MI]

Common Name

English

IOPROMIDE [EP IMPURITY]

Common Name

English

1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-5-((METHOXYACETYL)AMINO)-N-METHYL-

Systematic Name

English

Iopromide [WHO-DD]

Common Name

English

IOPROMIDE [VANDF]

Common Name

English

IOPROMIDE [JAN]

Common Name

English

IOPROMIDE [EP MONOGRAPH]

Common Name

English

IOPROMIDE [USP-RS]

Common Name

English

IOPROMIDE [USP MONOGRAPH]

Common Name

English

N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-5-(2-METHOXYACETAMIDO)-N-METHYLISOPHTHALAMIDE

Systematic Name

English

ZK-35760

Code

English

iopromide [INN]

Common Name

English

IOPROMIDE [ORANGE BOOK]

Common Name

English

IOPROMIDE [USAN]

Common Name

English

ULTRAVIST

Brand Name

English

IOPROMIDE [MART.]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000180185